Pramodini MedicareShare price, financial results, shareholding and management
- Market cap
- ₹230 cr
- Stock P/E
- 13.5peers 15.4
- Book value
- ₹24
- Price to book
- 4.35
- EV / operating profit
- -
- Market cap to sales
- 3.71
- ROCE · FY26
- 41.0%
- ROE · FY26
- 38.6%
- ROE, 3-year average
- 36.2%
- Operating margin · FY26
- 50.0%peers 18.7%
- Sales growth, 3 years
- 26.0%
- Profit growth, 3 years
- 41.5%
- Debt to equity
- 0.34peers 0.17
- Borrowings
- ₹18 cr
- Interest cover
- 24.0×
- Cash from business / op. profit
- 81%
- Debtor days
- 102
- Pledged
- 0.00%
- Promoter holding
- 62.64%
- Change in promoter holding
- -
- Shareholders
- 1,144
- High / low since listing
- ₹137 / ₹97
- Dividend yield
- 0.00%
- Face value
- ₹10
Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.
Pramodini Medicare share price chart
Close on 19 Nov 2026 · +1.21% on the day · Vol 33,600
Daily prices to 19 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.
Share price returns
To the close of 19 Nov 2026
- 1 month
- -9.3%
- 3 months
- -11.6%
- Since IPO
- -11.6%
- Traded a day, 20 days
- ₹0.36 cr
- Taken for delivery
- 80%
Business growth
Sales and net profit, from the reported results
| Sales | Profit | |
|---|---|---|
| FY26 on FY25 | +63% | +55% |
| 3 years, a year | +26% | +42% |
About Pramodini Medicare: business, products and customers
Pramodini Medicare runs scan and test centres, mostly MRI, CT and X-ray rooms set up inside government and private hospitals, and is paid for each scan it does. Its shares trade on NSE Emerge.
Pramodini Medicare was set up in 2000 and has been led since 2015 by Dr. Chalasani Kuldeep Kumar, a radiologist, and Dr. Chalasani Kavitha. It puts its own scanning machines and technicians into hospitals under agreements with state governments, private hospitals and public sector companies, and also runs its own centres in Vijayawada with a laboratory and a round-the-clock remote reporting desk. Radiology gives almost all its sales; a small lab business and a nuclear medicine service started in FY26 make up the rest.
It works through 16 centres in 14 cities across seven states, with Andhra Pradesh still the largest market. Government hospital partnerships gave about half of FY26 sales, a private hospital partner in Karnataka about a fifth, and a public sector partner in West Bengal and its own centres the rest. In FY26 it more than doubled its machinery, and the number of tests it ran nearly doubled.
Read more about the business
What is new: the shares listed on NSE Emerge in August 2026, and the issue money is meant to pay for equipment at a new centre in Bangalore and at centres in Hubli, Manjeri and Vijayawada. In September 2026 the company took 30% of a new company formed to run a cardiac facility at the Kodagu Institute of Medical Sciences in Karnataka for ten years, a deal it says is with related parties.
From the red herring prospectus (August 2026) and the company's exchange filing of 22 September 2026.
Read the deeper study ↓In its favour
- Sales have grown fast: 26% a year over three years.
- It earns a high return on the money it uses: ROCE 41% in FY26.
- It brings in more cash than it shows as profit: ₹25 cr against ₹17 cr in FY26.
- The promoters own a large part of the company: 62.64%.
To watch
- Spending of ₹45.1 cr of issue money on scanners for Bangalore, Hubli, Manjeri and Vijayawada during FY27 (Red herring prospectus, p.101 and p.102).
- Start of the Kodagu cardiac facility through Sidheart Advanced Healthcare, 30% held, under a ten-year concession (Exchange filing, 22 Sep 2026, p.2 to p.4).
- Recovery of the ₹7.3 cr lent to the loss-making associate Vista Pramodini Medicare (Red herring prospectus, p.235 and p.247).
- Renewal of the fixed-term hospital agreements, which the authorities may put out to tender again (Red herring prospectus, p.35).
- Its borrowings rose a lot last year: ₹18 cr, from ₹11 cr.
From the company's documents first, then the reported figures read by fixed rules, the same for every company. Facts, not a view on the shares.
Pramodini Medicare revenue and profit growth
Half-yearly results · Profit and lossSales have grown fast. Last year profit grew more slowly than sales, so the profit kept from each rupee of sales slipped.
Pramodini Medicare profit and loss
Full years to March, FY22 to FY26 · ₹ crore, consolidated where reported
| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Sales | 25 | 31 | 35 | 38 | 62 |
| Expenses | 13 | 16 | 20 | 17 | 31 |
| Operating profit | 12 | 15 | 16 | 21 | 31 |
| OPM | 49.0% | 49.0% | 44.0% | 55.0% | 50.0% |
| Other income | 0 | 0 | 1 | 0 | 1 |
| Interest | 2 | 2 | 2 | 1 | 1 |
| Depreciation | 4 | 5 | 4 | 4 | 7 |
| Exceptional and other items | 1 | · | -1 | · | -1 |
| Profit before tax | 7 | 8 | 10 | 16 | 23 |
| Tax rate | 28.6% | 25.0% | 30.0% | 31.2% | 26.1% |
| Net profit | 5 | 6 | 7 | 11 | 17 |
| EPS ₹ | 4.92 | 4.76 | 5.40 | 85.89 | 10.41 |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Exceptional and other items: profit before tax beyond operating profit, other income, interest and depreciation, such as one-off items or a share of associates' profit, as reported.
Earnings per share before FY25 is on the share count of that time, before later bonus or share issues, so it does not compare with the years after.
Pramodini Medicare profitability
Margins and returns on capitalLast year the company kept less from each rupee of sales than the year before. It earns a high return on the money it uses.
Operating margin, every year
Per cent of sales kept before interest, depreciation and tax
| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Operating margin | 49.0% | 49.0% | 44.0% | 55.0% | 50.0% |
| Tax rate | 28.6% | 25.0% | 30.0% | 31.2% | 26.1% |
| ROCE | · | 26.3% | 31.6% | 41.5% | 41.0% |
| ROE | · | 40.0% | 32.6% | 37.3% | 38.6% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Pramodini Medicare debt and cash flow
Balance sheet · Cash flow · Working capitalThe company's own money, its net worth, has grown fast. It borrowed much more last year. Its loans are smaller than its own money. Last year the business brought in more cash than it showed as profit. It spent more on assets and investments than the business brought in, and raised the rest from loans or shares. Customers pay faster than they did in FY24, which frees up the company's money.
Bars below the line are cash going out.
Pramodini Medicare balance sheet
At each 31 March · ₹ crore
| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Equity capital | 1 | 1 | 1 | 1 | 17 |
| Reserves | 10 | 18 | 23 | 34 | 36 |
| Net worth | 11 | 19 | 24 | 35 | 53 |
| Borrowings | 25 | 21 | 12 | 11 | 18 |
| Other liabilities | 5 | 10 | 13 | 10 | 23 |
| Total liabilities | 41 | 50 | 49 | 56 | 94 |
| Fixed assets | 26 | 22 | 16 | 22 | 44 |
| Capital work in progress | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| Other assets | 15 | 28 | 33 | 34 | 50 |
Pramodini Medicare cash flow
₹ crore
| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Cash from operations | 12 | 6 | 10 | 22 | 25 |
| Cash from investing | -12 | -1 | -1 | -15 | -31 |
| Cash from financing | 3 | -2 | -11 | -2 | 6 |
| Net cash flow | 3 | 3 | -2 | 5 | 0 |
Working capital
Days
| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Debtor days | 109 | 172 | 186 | 107 | 102 |
| Cash conversion cycle | 109 | 172 | 186 | 107 | 102 |
| Working capital days | -66 | -36 | 16 | 0 | 2 |
Pramodini Medicare peers and competitors
Listed SME companies in the same industryBy sales, Pramodini Medicare is number 9 of the 23 listed SME companies in healthcare services.
Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.
| Company | Market cap ₹ cr | P/E | Sales ₹ cr | Profit ₹ cr | Op. margin | Debt/equity |
|---|---|---|---|---|---|---|
| Hannah Joseph Hospital | 236 | 21.5 | 92 | 11 | 27.0% | 0.28 |
| Star Imaging And Path Lab | 133 | 7.0 | 89 | 19 | 37.0% | 0.18 |
| Nephro Care India | 141 | 41.9 | 88.7 | 3.4 | 9.4% | 0.00 |
| Modern Diagnostic & Research Centre | 95 | 18.1 | 83.1 | 5.3 | 15.4% | 0.63 |
| Pramodini Medicare | 230 | 13.5 | 62 | 17 | 50.0% | 0.34 |
| Adeshwar Meditex | - | - | 56.1 | 1.3 | 4.9% | 0.16 |
| ABH Healthcare | 52 | 9.3 | 51.6 | 5.6 | 28.8% | 3.17 |
| Shanmuga Hospital | 57 | 13.4 | 45 | 4.2 | 18.4% | 0.16 |
| Maitreya Medicare | 80 | - | 44.9 | -2.5 | -0.7% | 0.80 |
| Invicta Diagnostic | 84 | 17.3 | 32.4 | 4.9 | 30.2% | 0.07 |
| Nidan Laboratories and Healthcare | 19 | 12.4 | 25.5 | 1.5 | 19.0% | 0.16 |
| Median of the 10 others | 84 | 15.4 | 53.9 | 4.5 | 18.7% | 0.17 |
Pramodini Medicare shareholding pattern
Promoters, FIIs, DIIs, HNIs and small holdersThe promoters own more than half the company. Foreign and Indian funds own a noticeable share.
Pramodini Medicare shareholding pattern
Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.
| Aug 26 | |
|---|---|
| Promoters | 62.64% |
| Foreign investors (FIIs) | 2.84% |
| Indian institutions (DIIs) | 8.64% |
| HNIs (over ₹2 lakh each) | 10.82% |
| Small holders (up to ₹2 lakh) | 11.73% |
| Companies and others | 3.33% |
| Number of shareholders | 1,144 |
The named holders are at 18 Aug 2026, each under the group the pattern files them in.
Pramodini Medicare study: the business from its own documents
Read from 1 of the company's own documentsPramodini Medicare so far
From the company's own record
- 19 Aug 2026Listed on NSE Emerge at ₹118
- 31 Aug 2026Promoters at 62.64%
- 8 Sept 2026Highest close since listing, ₹129.55
Pramodini Medicare key facts from the filings
Each figure with the document it comes from
- Centres
- 16
- Diagnostic centres in 14 cities across seven states, including one in Kerala yet to start.Red herring prospectus, p.140 and p.143
- Radiology share
- 97.05%
- Share of FY26 sales from scans such as MRI, CT, X-ray and ultrasound.Red herring prospectus, p.29
- Tests run
- 4,74,419
- Tests in FY26, up from 2,54,765 in FY25, led by MRI, CT and X-ray.Red herring prospectus, p.141
- Largest customer
- 44.17%
- Share of FY26 sales from the single largest customer, down from 63.88% in FY24; the top five gave 64.32%.Red herring prospectus, p.30
- Government partnerships
- 54.19%
- Share of FY26 sales from centres in government hospitals, down from 77.22% in FY24 as private and PSU work grew.Red herring prospectus, p.29
Show 5 more facts
- Andhra Pradesh
- 61.90%
- Share of FY26 sales from Andhra Pradesh, down from 86.66% in FY24 as Karnataka and West Bengal were added.Red herring prospectus, p.143
- Equipment bought
- ₹29.3 cr
- Medical equipment bought in FY26; plant and equipment rose to ₹44.2 cr from ₹21.8 cr.Red herring prospectus, p.317
- Issue money for machines
- ₹45.1 cr
- Planned for scanners at a new Bangalore centre and at Hubli, Manjeri and Vijayawada during FY27.Red herring prospectus, p.101 to p.103
- Loan to associate
- ₹7.3 cr
- Owed at March 2026 by loss-making associate Vista Pramodini Medicare, up from ₹5.5 cr; the company's unbooked share of its losses was ₹6.1 cr.Red herring prospectus, p.235 and p.247
- Cardiac venture
- 30%
- Stake taken in Sidheart Advanced Healthcare, formed to run the Kodagu cardiac facility for ten years; a related party deal.Exchange filing, 22 Sep 2026, p.2 to p.4
What the company said, and what happened
The company's own statements, attributed, set against what it later reported; not newboard's estimates
The company does not state an order book; its centres run under agreements with hospitals for set terms. The offer document plans to spend the issue money on equipment during FY27, for a new centre in Bangalore, a centre at Manjeri in Kerala that has yet to start, more machines at Hubli and a replacement at Vijayawada. The company also holds a letter of award from the Government of Karnataka for a cardiac facility at Kodagu and a notification of award in Madhya Pradesh.
Is it a good business? Six questions
Each answer is about that one question, read from the documents; tap one for the evidence. Not a view on the shares.
Pramodini Medicare earns its money by placing scanners inside hospitals and charging for each scan, and once a machine is busy most of the extra income turns into profit.
Its weak spots are a heavy lean on a few government and hospital contracts that must be won and renewed on price, steady spending on costly machines, and money lent to a loss-making associate.
WatchCan it set its own prices?No. Government work is won by tender, usually by the lowest bid, and the company says cutting prices to win can hurt margins.
AverageHow strong is it against rivals?It has a doctor-led team, its own machines placed inside hospitals and a record of winning hospital agreements, but larger diagnostic chains compete for the same work.
WatchWho are its customers?Mostly governments and hospitals, with one customer giving close to half the sales, though that share is falling.
WatchDoes it need a lot of money?Yes. Each new centre needs costly scanners bought up front, and government payers can be slow.
StrongCan it keep finding new work?It has added new states, partners and services in each of the last few years.
AverageDo good and bad years swing a lot?Scans are needed in every season and sales have grown each year, but margins move as new centres open and fill up.
Who runs Pramodini Medicare?
Promoters, directors and officers; tap a name for the background
DCDr. Chalasani Kuldeep KumarPromoter, Chairman and Managing Director · holds 35.71%
MBBS from Nagpur University (2002) and MD in radio-diagnosis from Rajiv Gandhi University of Health Sciences, Karnataka (2006). Earlier Chief Resident at Grant Medical College and Sir J.J. Group of Hospitals, Mumbai, and Associate Professor at Dr Pinnamaneni Siddhartha Institute of Medical Sciences. More than 20 years in medicine and radio-diagnosis; with the company since 2015 and in charge of its overall management. FY26 pay was ₹0.60 cr.
Red herring prospectus, p.181, p.183 and p.240DCDr. Chalasani KavithaPromoter and Non-Executive Director · holds 6.77%
MBBS and MS in obstetrics and gynaecology from Kasturba Medical College, Manipal, DNB in the same field and a fellowship in gynaecological endoscopy, with more than 20 years in the field. With the company since 2015; works on partnerships and new business. The prospectus states Dr. Chalasani Kavitha is the wife of Dr. Chalasani Kuldeep Kumar.
Red herring prospectus, p.181, p.183, p.184 and p.185SRSri Ram Medicare Private LimitedPromoter company · holds 20.16%
Incorporated in Vijayawada in March 2012; owned and directed by Dr. Chalasani Kuldeep Kumar, Dr. Chalasani Kavitha and Ms. Chalasani Lalithakumari.
Red herring prospectus, p.198MCMs. Chalasani Durga AashrithaPromoter and Non-Executive Director
A medical student in the third professional MBBS course at Dr. Pinnamaneni Siddhartha Institute of Medical Sciences; on the board since September 2025. The prospectus states Ms. Chalasani Durga Aashritha is the daughter of Dr. Chalasani Kuldeep Kumar and Dr. Chalasani Kavitha.
Red herring prospectus, p.182, p.184 and p.185MCMs. Chalasani LalithakumariPromoter
MBBS from Andhra University (1974) and a diploma in gynaecology and obstetrics from Nagarjuna University (1978); associated with Sri Ram Medicare Private Limited since 2012. Not a director of the company.
Red herring prospectus, p.198MRMr. Rajkamal KonaChief Financial Officer
M.Com from Acharya Nagarjuna University, with 12 years in accounts and finance at firms including National Small Industries Corporation and Sarvani Industries. Chief Financial Officer since January 2026.
Red herring prospectus, p.194MPMr. Potturi Srinivasa Naga Venkata Krishna KishoreChief Operating Officer
BCA from Nagarjuna University and a master's in hospital management from Osmania University, with more than 18 years in hospital administration at NRI Academy of Sciences, NRI Medical College and GMR Varalakshmi CARE Hospital. With the company since September 2021.
Red herring prospectus, p.194DEDr. Eshwar Chandra NanduryIndependent Director
MBBS from Kakatiya University and MD in radiodiagnosis from PGIMER, Chandigarh, with over 31 years in radiology; head of radiology and senior consultant at Yashoda Hospitals. On the board since January 2026.
Red herring prospectus, p.182, p.183 and p.184MMMr. Manas DashIndependent Director
B.Com (Hons.) and LL.B. from Utkal University and a fellow chartered accountant, practising since 2003 with over 22 years of experience. On the board since January 2026.
Red herring prospectus, p.183 and p.184Pramodini Medicare latest news and announcements
Announcements · Documents · Corporate actionsPramodini Medicare announcements
10 on record, latest first; each opens the filing on the exchange
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Certificate under SEBI (Depositories and Participants) Regulations, 2018PDF ↗
- Structural Digital DatabaseSDD Certificate for Quarter ended Sept 2026PDF ↗
- Integrated Filing- GovernancePramodini Medicare Limited has informed regarding Submission of the Compliance Report on Corporate Governance for the Q2 ended 30 September 2026 for FY 2026-27 PDF ↗
- General UpdatesGeneral UpdatesPDF ↗
- Registrar & Share Transfer Agent UpdateRegistrar & Share Transfer Agent UpdatePDF ↗
- General UpdatesGeneral UpdatesPDF ↗
- Disclosure of material issuePramodini Medicare Limited has informed regarding Disclosure of material issuePDF ↗
- AcquisitionAcquisitionPDF ↗
- AppointmentOf Mr RAMANA MURTHY as Other of the company w.e.f. September 09, 2026PDF ↗
- Outcome of Board MeetingHeld on September 09, 2026PDF ↗
Pramodini Medicare annual reports, earnings calls and documents
Every document links to its source; “read” marks those this page is built from
- Offer document ↗read
Pramodini Medicare share split, bonus and dividends
From the corporate actions the company announces on the exchange
No share split, bonus issue or dividend is on record since listing.
Checks we ran on Pramodini Medicare's data · 7
Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.
- ✓Balance sheet totals add up for FY25 and FY26.
- ✓Market cap uses the share count in the latest shareholding pattern (2,20,45,595 shares).
- !The FY26 results imply 1,70,00,000 shares at face value ₹10, which disagrees with the shareholding pattern; the pattern is used.
- ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
- !Earnings per share changes basis between FY24 (₹5.40) and FY25 (₹85.89) because the share count behind it changes; EPS is shown as reported, and growth is worked out on profit.
- ✓Revenue and profit are reported for every year shown, FY22 to FY26.
- iPrices run to the close on 14 Oct 2026, from the exchange's daily figures.
Questions people ask about Pramodini Medicare
What does Pramodini Medicare do?
Pramodini Medicare runs scan and test centres, mostly MRI, CT and X-ray rooms set up inside government and private hospitals, and is paid for each scan it does. Its shares trade on NSE Emerge.
What is the share price of Pramodini Medicare?
₹104 at the close on 19 Nov 2026, from the exchange's daily figures.
What is the market cap of Pramodini Medicare?
₹230 cr at the close on 19 Nov 2026, on 2,20,45,595 shares.
What is the P/E of Pramodini Medicare?
13.5 times FY26 profit at the close on 19 Nov 2026 (our arithmetic).
What are Pramodini Medicare's revenue and profit?
Revenue ₹62 cr and profit after tax ₹17 cr in FY26.
Who are the promoters of Pramodini Medicare?
Dr. Chalasani Kuldeep Kumar, Dr. Chalasani Kavitha, Sri Ram Medicare Private Limited, Ms. Chalasani Durga Aashritha, Ms. Chalasani Lalithakumari; promoters held 62.64% at 31 Aug 2026.
What was the IPO price of Pramodini Medicare?
₹118 a share; it listed on 19 Aug 2026.
More SME companies like Pramodini Medicare
Other listed SME companies in healthcare services, the closest in size first, each read from its own documents.
- Aashka HospitalsAASHKA · BSE SME · Healthcare ServicesMarket cap ₹229 cr
- Hannah Joseph HospitalHANNAH · BSE SME · Healthcare ServicesMarket cap ₹246 cr
- Asarfi HospitalASARFI · BSE SME · Healthcare ServicesMarket cap ₹341 cr
- Nephro Care IndiaNEPHROCARE · NSE Emerge · Healthcare Services · listed 2024Market cap ₹149 cr
- Star Imaging And Path LabSTARIMAGIN · BSE SME · Healthcare ServicesMarket cap ₹101 cr
- Invicta DiagnosticINVICTA · NSE Emerge · Healthcare Services · listed 2025Market cap ₹97 cr
Every listed SME company in Healthcare Services → · SME companies listed in 2026 →
Built from 1 offer document, 10 exchange announcements, 1 shareholding patterns and 5 years of reported results. Every figure carries its source; where the documents are silent, the page says so.